consideration of dose escalation 6 months : Formal assessment of treatment efficacy according to appropriate criteria: For diabetes (NICE NG28): HbA1c reduction of at least 11 mmol/mol (1.0%) and weight loss of at least 3% For weight management: At least 5% weight loss from baseline on maintenance dose (per SmPC and NICE guidance) Annually thereafter : Ongoing monitoring of metabolic parameters, cardiovascular risk factors, and treatment appropriateness Treatment adjustments may be necessary if: Side effects remain intolerable despite supportive measures Weight loss plateaus before reaching target (may warrant dose increase if not at maximum) Inadequate glycaemic control persists (may require additional diabetes medications) Significant weight loss goals are achieved (maintenance strategies and potential dose reduction) Patients should maintain open communication with their healthcare team, reporting both positive developments and concerns
Store immediately in the refrigerator at 36-46F (2-8C)
Common side effects of GLP-1 medications include: - Nausea - Diarrhea - Vomiting - Constipation Side effects are typically mild and temporary
21, 2024, three generic versions of liraglutide (Victoza) for the treatment of T2DM are commercially available in the U.S
For understanding the specific triple mechanism of retatrutide, the complete retatrutide dose guide provides additional pharmacological detail
Minimizing Risks After Discontinuation To minimize these risks, healthcare providers may recommend a few targeted strategies
)
